Search
理事单位
通知通告
泽璟公司1.1类抗肿瘤新药“新普生”进入临床一期!
 
“苏州瑞博与Quark公司开发的小核酸药物QPI-1007在中国的国际多中心临床试验于近日正式获CFDA批准,这是中国第一个获批临床试验的小核酸药物!
 
欧凯纳斯科技江苏有限公司

OKeanos develops organic chemistry. Starting from heterocycles, we are moving into modified nucleotides and unnatural amino acids. In these fields, we combine R&D taskforce and production facility. Strong funding and high-tech platform enable fast and efficient R&D and production of gram to kilogram to ton scale of heterocycles, modified nucleotides and unnatural amino acids. As a knowledge-based organization, OKeanos builds up real expertise. We collaborate with pharmaceutical giants and biotech companies around the world, providing solutions to clients and work together with partners to move faster.

OKeanos is fully committed to the clients/partners, IP protection, confidentiality, integrity, efficiency and quality. Our path to success is predicted based on the following:

Collaboration first. We are fully committed to ensuring the success of our collaborations with clients/partners. We achieve this by combining the high quality people with world

版权所有: 江苏省小核酸产业技术创新战略联盟  苏ICP备15009132号
CopyRight © 2010 www.ksrnai.com All Rights Reserved  地址:江苏省昆山市玉山镇元丰路168号
电话:+86-(0)512-50331002  传真:+86-(0)512-57017805  技术支持:网联信息